Company Overview: Intelli Pharmaceutics

About the Company

Intelli Pharmaceutics
Facebook Tweeter Linkedin

Intellipharmaceutics International (NASDAQ: IPCI; TSX: I) is engaged in the research, development, and commercialization of controlled-release and targeted pharmaceutical products. Controlled-release means releasing a drug into the bloodstream or at a target site in the body, over an extended period of time or at predetermined times. In some circumstances, controlled-release drug delivery can enhance efficacy and patient compliance as compared to immediate release formats for the same drug.

The company’s proprietary Hypermatrix™ technology is at the core of their controlled-release drug delivery approach. The flexibility of the Hypermatrix™ technology allows for the intelligent and efficient design of drugs through the precise control of a number of key variables. This allows the company to respond to varying drug attributes and patient requirements, producing a desired controlled-release effect in a time and cost-effective manner. Intellipharmaceutics is applying its technology to the development of both existing and new pharmaceuticals across a range of therapeutic classes.

The flexibility and the competitive advantage of the Hypermatrix™ technology allow them to focus our development activities in two niche markets:

  • Difficult-to-produce controlled-release generic drugs (ANDA regulatory path)
  • Improved current therapies through controlled release (NDA regulatory path)

Investor Toolkit

Multimedia

Company News

Email Subscription

Follow

Follow this blog

Get every new post delivered right to your inbox.

Email address